Citigroup - Mylan "buy"

Datum Erster Hoch Tief Schluss     Stücke Volumen
  23.11.12     26,63     27,31§26,57 27,11 $ 3.160.546 85,1 M
wenn das so weitergeht bis morgen früh ja früh ..stehn wir im Alkohol bis an die Knie ..holladiehiiiiiie  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  26.11.12     27,00     27,07§26,63 26,99 $ 5.989.790 150 M
Bilanz Nasdaq und Parkett Frankurt hat sich wer 500 Stücke geangelt ..ät läuft  

http://www.ariva.de/news/Mylan-Aktie-outperform-Credit-Suisse-4353528 Pott:+186,61% ,GrB  

200 Stücke haben sich bereits auf der Nasdaq-Briefseite eingefunden zu einem Einkaufspreis von nur 27,25 $ dann mal tau  

10:37 29.11.12

Vancouver (www.aktiencheck.de) - Die Analysten von Canaccord Genuity bewerten die Aktie von Mylan (Mylan Aktie) mit dem Votum "buy". Das Kursziel werde von 30,00 USD auf 31,00 USD erhöht. (Analyse vom 28.11.2012) (29.11.2012/ac/a/a)

Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
Quelle: Aktiencheck  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  29.11.12     27,29     27,45§27,16 27,29 $ 3.733.077 95,3 M
Nasdaq  

Mylan Launches Generic Detrol® Tablets

13:35 29.11.12

PR Newswire

PITTSBURGH, Nov. 29, 2012

PITTSBURGH, Nov. 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate Tablets, 1 mg and 2 mg. This product is the generic version of Pharmacia and Upjohn's Detrol® Tablets and is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Tolterodine Tartrate Tablets USP, 1 mg and 2 mg, had U.S. sales of approximately $61.5 million for the 12 months ending Sept. 30, 2012, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 174 ANDAs pending FDA approval representing $79.5 billion in annual sales, according to IMS Health. Thirty-six of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.
Quelle: PR Newswire  

http://www.ariva.de/news/...h-2013-2014-Antiretroviral-Tender-4361431 GrB  

Mylan Selected As One of the Leading Suppliers to the South African National Department of Health 2013/2014 Antiretroviral Tender

15:15 29.11.12

PR Newswire

JOHANNESBURG and PITTSBURGH, Nov. 29, 2012

JOHANNESBURG and PITTSBURGH, Nov. 29, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that its subsidiary in India, Mylan Laboratories Ltd., a leading manufacturer of antiretroviral (ARV) drugs, has been selected, through its South African-based subsidiary Mylan (Proprietary) Limited (Mylan Limited), as one of the leading suppliers of ARV drugs to the South African National Department of Health for the tender period January 1, 2013 to December 31, 2014.

Mylan Limited secured a R1.12 billion share, which represents 19.1% of the R5.9 billion tender value. As a part of this award, Mylan will supply the South African Government with 31% of the 30 million units of triple therapy fixed dose combination (FDC) called for in the tender. Mylan is pleased to support the Government's initiative to move to triple therapy FDC treatment regimens in South Africa, as such regimens can simplify treatment and improve patient adherence.

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people access to high quality medicines, including affordable ARVs. Only through access to these vital medicines can we stem the tide of HIV/AIDS in South Africa and around the world. This award reinforces Mylan's commitment to provide high quality advanced drugs to help people suffering from HIV/AIDS in South Africa, and we are proud to have been selected as a partner to the South African Department of Health."

"We believe Mylan's selection as a leading supplier to the South African Government's ARV tender reflects our vertical integration, quality manufacturing, global scale and proven-track record of being a reliable partner in supplying affordable ARV medicines across the world. We are pleased to bring this global scale, quality and reliability to the South African market and continue our legacy in fighting HIV/AIDS," said Paul Miller, Managing Director and Vice President of Mylan's South African business.

Mylan supplies ARV drugs to more than 120 countries around the world and approximately one-third of HIV/AIDS patients receiving treatment in developing countries depend on a Mylan ARV product. Mylan will be entering the South African market with a comprehensive portfolio of ARV drugs, consisting of first- and second-line adult and pediatric therapies, including several dual and triple FDCs.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
Quelle: PR Newswire  

http://www.ariva.de/news/...-Commemorates-24th-World-AIDS-Day-4363902  

Zeit    Kurs Stück
  08:15:27§20,93 € 230
Parkett Frankfurt
GLÜCKWUNSCH  

307.537 shares durch den Ticker gedonnert  

news
http://www.nytimes.com/2012/12/04/business/...partner=rss&emc=rss
GrB  

................2006 2007 2008 2009 2010 2011
    Umsatz     1.240     1.587     4.631     5.015     5.404     6.106§
Pott +275,00%
buran  

RT +0,20%
   BranchePharmazie
  Herkunft USA          §
Indizes/Listen§NASDAQ 100, S&P 500
Aktienanzahl§426,7 Mio. (Stand: 31.12.11)
 Marktkap.§11.694 Mio. $
GrB  

http://www.mylan.com/  

Mylan Launches Generic Version of Atacand HCT®

14:45 05.12.12

PR Newswire

PITTSBURGH, Dec. 5, 2012

PITTSBURGH, Dec. 5, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 16/12.5 mg, 32/12.5 mg and 32/25 mg. This product is the generic version of AstraZeneca's Atacand HCT®, and is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy.(1)  

Mylan was the first company to have submitted a substantially complete ANDA to the FDA containing a Paragraph IV certification for Candesartan Cilexetil and Hydrochlorothiazide Tablets, 32/25 mg, and was awarded 180 days of generic drug marketing exclusivity for this product strength. Mylan is shipping all approved strengths of this product immediately.

Atacand HCT had U.S. sales of $56.3 million for the 12 months ending Sept. 30, 2012, according to IMS Health.

Currently, Mylan has 178 ANDAs pending FDA approval representing $80.1 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(1) Candesartan Cilexetil and Hydrochlorothiazide Tablets can cause injury and death to the developing fetus and therefore should be discontinued if pregnancy occurs. This product is contraindicated in patients who are hypersensitive to any component of this product or to other sulfonamide-derived drugs and in patients with anuria. Other precautions include: excessive reductions in blood pressure, decreased renal function, allergic reactions, exacerbation or activation of systemic lupus erthematosus, drug interactions with lithium, potassium and electrolyte abnormalities, visual changes and metabolic disturbances.  If any of these conditions occur or are suspected, medical attention should be sought.

SOURCE Mylan Inc.
Quelle: PR Newswire  

Preis 27,30 $ Inhalt 200 spread 0,37% buran  

27,35 USD wurden angezeigt und im ask schon die nächsten 200 unddddd ENTER
ab die Luzi  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  06.12.12     27,30     27,35§27,09 27,31 $ 4.108.801 110 M
ohne Manko ..sehr schön gahalten,sogar noch grün geschlossen ..sehr stabil ..gute Geldanlage  

Handelsplatz Letzter Veränderung Vortag letzte Stk. Tag-Stk. Kursspanne Zeit

 Tradegate§21,26  € +1,33% 20,98 € 250 250 21,26 -  21,26 09:08:46  

27,90 $ +2,34% +0,64 $
In Euro: 21,564 € | Nasdaq
^^^^^^^^^^^^^^^^^^^das kommt dann alles mit rein in Pott ..rubbeldiebubbeldeiwixxxxx  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  10.12.12     27,22     28,10§27,15 28,02 $ 5.965.891 163 M

GrB  

http://www.ariva.de/news/...Announces-Pricing-of-Senior-Notes-4377661  

AstraZeneca setzt sich im Patentstreit um Crestor vorerst durch

18:25 14.12.12

LONDON/WASHINGTON (dpa-AFX) - Der zweitgrößte britische Pharmakonzern AstraZeneca (Astrazeneca Aktie) (Astrazeneca Aktie) kann vorerst aufatmen. Das US-Berufungsgericht in Washington bestätigte die Gültigkeit des Patents für den Blutfettsenker Crestor, wie es am Freitag mitteilte. Der Generika-Hersteller Mylan (Mylan Aktie) hatte den Patentschutz angezweifelt.

AstraZeneca leidet bereits seit geraumer Zeit unter der Konkurrenz billiger Nachahmermittel. Crestor hatte im dritten Quartal einen Umsatz von 1,5 Milliarden US-Dollar eingebracht./she/stw
Quelle: dpa-AFX